Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

(2012) José Baselga et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-Adjusting Capecitabine Minimizes Adverse Effects While Maintaining Efficacy: A Retrospective Review of Capecitabine for Metastatic Breast Cancer

(2011) Robert Leonard et al.   Clinical Breast Cancer

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2011) Adam M. Brufsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

(2011) Martin R. Stockler et al.   JOURNAL OF CLINICAL ONCOLOGY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

(2011) Heikki Joensuu et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?

(2010) C. Zielinski et al.   ANNALS OF ONCOLOGY

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

(2010) Gabriel N. Hortobagyi et al.   BREAST CANCER RESEARCH AND TREATMENT

Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials

(2010) Joanne L. Blum et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

(2010) Carlos H. Barrios et al.   BREAST CANCER RESEARCH AND TREATMENT

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial

(2010) M. Kaufmann et al.   EUROPEAN JOURNAL OF CANCER

Safety of capecitabine: a review

(2010) Sameh E Mikhail et al.   Expert Opinion On Drug Safety

Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2010) Joseph A. Sparano et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

(2009) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer

(2009) Mikihiro Kusama et al.   Breast Cancer

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

(2008) David Cameron et al.   BREAST CANCER RESEARCH AND TREATMENT